GSK and Ionis announced positive topline results from two Phase 3 registrational trials of bepirovirsen, an antisense oligonucleotide for chronic hepatitis B. The B‑Well 1 and B‑Well 2 studies together enrolled more than 1,800 patients across 29 countries and met primary efficacy and safety endpoints, according to a company release. GSK licensed bepirovirsen from Ionis and has been leading late‑stage development. The programs target functional cure—sustained viral suppression without continuous therapy—a high bar that, if confirmed in full data and regulatory review, could reshape therapeutic options for chronic hepatitis B. GSK and Ionis will now prepare regulatory interactions and next steps toward filings.